Risk factors for infection by oncogenic human papillomaviruses in HIV-positive MSM patients in the ART era (2010–2016)

Carmen Hidalgo-Tenorio, PhD, MDa, Concepción Gil-Anguita, MDa, Jessica Ramirez-Taboada, MDa, Javier Esquivias, PhD, MDb, Miguel A. López-Ruz, PhD, MDa, Omar Mohamed Balgahata, PhD, MDb, Carmen Hidalgo-Tenorio, PhD, MDa, Concepción Gil-Anguita, MDa, Jessica Ramirez-Taboada, MDa, Miguel A. López-Ruz, PhD, MDa, Omar Mohamed Balgahata, PhD, MDb, Rosario Javier-Martinez, PhD, MDa, Juan Pasquau, MDa

Abstract
Squamous cell carcinoma of anus (SCCA) is one of the most frequent non-AIDS-defining diseases in HIV patients, mainly in men who have sex with men (MSM), and it is associated with human papillomavirus (HPV) infection.

To determine the prevalence of high-risk HPV (HR-HPV) genotypes, premalignant lesions (HSIL) and SCCA in a cohort of HIV-positive MSM; to study the distribution of HPV genotypes according to anal histology results; and to analyze risk factors for this infection.

This prospective single-center study was conducted between May 2010 and September 2016. At the study visit, cotton swabs were used to collect anal samples for cytology study in ThinPrep Pap Test liquid medium (Thin Prep Processor 2000, Hologic Corp, USA), and for HPV PCR (Linear Array HPV Genotyping Test). After, high-resolution anoscopy (HRA) (Zeiss 150 fc) was carried out. Logistic regression analysis was performed to identify risk factors for HR-HPV infection.

The study included 319 patients, with mean age of 36.7 years; HR-HPV was detected in 81.3%. The prevalence of HSIL was 13.5% and SCCA was 0.3%. With regard to the distribution of HPV genotypes according to histology results, HPV 16 was the most frequent genotype in normal anal mucosa (26.7%), in LSIILs (36.9%), and in HSILs (38%). In multivariate analysis, CD4 nadir < 200 cells/µL was the factor associated with infection by HR-HPV (OR 3.66, 95% CI 1.05–12.75%).

High-risk MSM showed a high prevalence of HSIL+ lesions and of infection by oncogenic HPV, which appears to be favored by a deficient immune system. HPV 16 was the most frequently isolated genotype in anal mucosa, regardless of lesion type.

Abbreviations: ART = antiretroviral therapy, ASC = atypical squamous cells, HPV = human papillomavirus, HRA = high-resolution anoscopy, HR-HPV = high-risk HPV, HSIL = high-grade squamous intraepithelial lesion, LR-HPV = low-risk HPV, LSIIL = low-grade squamous intraepithelial lesion, MSM = men who have sex with men, SCCA = squamous cell carcinoma of anus.

Keywords: high-risk human papillomavirus, HIV, HSIL, men who have sex with men, squamous cell carcinoma of anus

1. Introduction
Human papillomavirus (HPV) infection is the most prevalent sexually transmitted disease worldwide and is more frequent among females, men who have sex with men (MSM), and immunodepressed patients (HIV, kidney transplant).[1] Infection with HPV, especially with oncogenic or high-risk HPV (HR-HPV), has been associated with squamous cell carcinoma of anus (SCCA) and cervical cancer.[2] SCCA is rare in the general population, with an incidence of around 1.8 cases per 100,000 persons/year.[11] However, it is one of the most frequent non-AIDS-defining neoplasms in HIV patients,[4] especially in MSM, with a very high incidence of up to 144 cases per 100,000 persons/year,[3] although survival rates are similar to those in the general population.[6] For this reason, it is of major interest to establish the prevalence of HPV infection in these patients as well as to study the distribution of HPV genotypes in relation to histological lesion type and identify predictive factors for this infection.

Data on the distribution of HPV genotypes related to anal mucosa histology have only been published on patients with abnormal cytology and with high-resolution anoscopy (HRA) findings suggestive of dysplastic lesion.[7] Moreover, the sensitivity of anal cytology to screen for high-grade squamous intraepithelial lesion (HSIL+) lesions (HSIL, CA) is variable and distribution of HPV genotypes according to anal histology results; and to identify the risk factors for HPV infection.

2. Patients and methods
2.1. Design
An observational, prospective, single-center study was conducted in a cohort of consecutive HIV-positive MSM enrolled between
May 2010 and September 2016 in a screening, diagnosis, treatment, and follow-up program for dysplastic anal mucosa lesions in the Infectious Diseases Department of a 3rd-level hospital in Southern Spain. This study was approved by the ethics committee of the hospital. Epidemiological, clinical, and analytical data were gathered and treated following the data protection law in force (Organic Law 15/1999, 13 December, of Personal Data Protection).

Inclusion criteria were: age ≥18 years, self-reported MSM, HIV positivity, and signing of informed consent to study participation. Exclusion criteria were: female sex, self-reported heterosexuality, and history of anal canal neoplasm.

At the visit, the variables collected were: age, history of perianal-genital condyloma, number of sexual partners as anorectal receptor during previous 12 months, utilization of condoms, smoking habit, alcohol consumption in standard drinking units (SDUs), parenteral drug addiction, nationality, educational level, months since HIV diagnosis, and HIV stage according to the CDC classification; months receiving antiretroviral therapy (ART), virological failure (viral-RNA >50copies/mL in at least 2 tests during the previous 6 months); and receipt of any concomitant treatment, and the presence of other infections, including chronic liver disease from hepatitis B (HBV) or hepatitis C (HCV) virus, syphilis, other sexually transmitted diseases, and latent, treated, or active tuberculosis infection. Analytical data were also gathered on CD4 nadir cell count, CD4 lymphocyte count and viral load at the HIV diagnosis, and on CD4, CD8, and viral load at the study visit.

During the study visit, 2 anal canal samples were taken using 2 cotton swabs impregnated in physiological saline: one for HPV detection and genotyping by qualitative polymerase chain reaction (PCR) (Linear Array HPV Genotyping Test) using a “GeneAmp PCR System 9700” thermocycler (Applied Biosystems, Roche, Switzerland); and the other for the cytology study; both samples were immersed in thin layer liquid medium for application of the thin-layer cytology technique using a ThinPrep Pap Test liquid medium (Thin Prep Processor 2000, Hologic Corp, Marlborough, MA). Both samples were sent to the pathology laboratory, and the results of both techniques were evaluated by a single pathologist (JE). Genotypes 16, 18, 26, 31, 33, 35, 39, 45, 51 to 53, 56, 58, 59, 66, 68, 73, and 82 were considered HR-HPVs, classifying genotypes 31, 33, 35, 52, 58, and 67 as subspecies of HPV 18, and genotypes 31, 33, 35, 52, 58, and 67 as subspecies of HPV 16. Genotypes 6, 11, 34, 40, 42 to 44, 54, 55, 57, 61, 70 to 72, 81, 83, 84, and 89 were considered low-risk HPVs (LR-HPVs).[11] Between 4 and 12 weeks after the study visit, patients underwent HRA with a Carl Zeiss 150 fc© retrograde cholangiopancreatography (ERCP) catheter. During the study visit, 2 anal canal samples were taken using 2 cotton swabs impregnated in physiological saline: one for HPV detection and genotyping by qualitative polymerase chain reaction (PCR) (Linear Array HPV Genotyping Test) using a “GeneAmp PCR System 9700” thermocycler (Applied Biosystems, Roche, Switzerland); and the other for the cytology study; both samples were immersed in thin layer liquid medium for application of the thin-layer cytology technique using a ThinPrep Pap Test liquid medium (Thin Prep Processor 2000, Hologic Corp, Marlborough, MA). Both samples were sent to the pathology laboratory, and the results of both techniques were evaluated by a single pathologist (JE).

The cytology study used the Bethesda classification,[12] which divides lesions into atypical squamous cells (ASC), ASC-high, low-grade squamous intraepithelial lesion (LSIL), and HSIL. The histology study used the classification of the Lower Anogenital Squamous Terminology (LAST) Standardization Project for HPV, which divides lesions into LSIL (AIN1/condyloma), HSIL (AIN2, AIN3), and SCCA.[13] These studies were always conducted by the same pathologist (JE).

### Definition of variables:

Abnormal cytology was considered to include ASC of unknown significance (ASCUS), LSIL, or HSIL.

In the histology study, “HSIL+ anal lesions” were considered to range from HSIL to SCCA, and “LSIL+ anal lesions” were from LSIL to SCCA.

Patients were considered late-presenters when the CD4 cell count was <200 cells/μL at HIV diagnosis.

#### Table 1: Baseline characteristics of the HIV-positive MSM patients.

| Characteristics | Number of patients n  = 319 |
|-----------------|----------------------------|
| Age (±SD)       | 36.7 (±10.2)               |
| <30 y, n, %     | 36 (30.1)                  |
| 30–50 y, n, %   | 196 (61.4)                 |
| >50 y, n, %     | 35 (11)                    |
| Median number of anal sexual partners in previous 12 m (IQR) | 1 (1–7) |
| Habitual use of condoms, n, %, 95% CI | 248 (77.7), (74.5–83.5) |
| Educational level |                             |
| No schooling    | 3 (0.9)                    |
| Primary school  | 36 (11.3)                  |
| Secondary school | 99 (31)                    |
| University      | 181 (56.7)                 |
| Retired, n, %, 95% CI | 21 (6.6), (3–9) |
| Origin          |                            |
| Europe          | 306 (96.0)                 |
| Central America | 13 (4.1)                   |
| History of anal/penile condyloma, %, 95% CI | 102 (32) |
| Anal/penile condyloma at baseline | 83 (26) |
| History of syphilis, n, %, 95% CI | 72 (22.6), (18–27) |
| History of other STD, n, %, 95% CI | 88 (27.6), (23–33) |
| Time since HIV diagnosis, m, (IQR) | 31 (9–91) |
| CD4 count at diagnosis of HIV, cells/μL, (±SD) | 456.8 (±512.5) |
| CD4 nadir, cells/μL, (±SD) | 381.3 (±234.9) |
| CD4 nadir <200 cells/μL, n, % | 78 (24.9) |
| CD4 count at baseline, cells/μL, (±SD) | 698.5 (±507.8) |
| CD8 count at baseline, cells/μL, (±SD) | 1244.6 (±2792.8) |
| HIV viral load at baseline (log) | 3.7 (±4) |
| Undetectable: <50 HIV RNA copies/mL of plasma n, % | 234 (73.7) |
| History of AIDS diagnosis, n, %, 95% CI | 89 (27.9), (23–33) |
| ART before inclusion, n, % | 273 (86.2) |
| Virological failure, n, % | 5 (1.8) |
| Median months with ART, P25–P75 | 19 (66–665) |
| Chronic HIV infection, n, % | 11 (3.4) |
| Chronic HBV infection, n, % | 9 (2.8) |
| Smoking, n, %, 95% CI | 160 (52.2), (45–56) |
| EXPDA, n, % | 2 (0.6) |

AIDS = acquired immune deficiency syndrome, ART = antiretroviral therapy, CI = confidence interval, EXPDA = ex-parenteral drug addict, HIV = hepatitis B virus, HCV = hepatitis C virus, IQR = interquartile range, MSM = men who have sex with men, SD = standard deviation, STD = sexually transmitted disease, VL = viral load.
quantitative variables that were normally distributed and the Mann–Whitney U test for those that were not, while the Pearson chi-square test was used for qualitative variables that were normally distributed and Fisher test for those that were not. The Kappa index was used to analyze the concordance between HR-HPV PCR and biopsy results, considering k < 0.20 poor, 0.21 to 0.40 weak, 0.41 to 0.60 moderate, 0.61 to 0.80 good, and 0.81 to 1.00 very good agreement, following Landis and Koch test.\(^\text{[14]}\)

Multivariate logistic regression analysis was performed, based on Freeman formula \(n = 10 \times (k + 1)\)\(^\text{[15]}\). The model included variables that were statistically significant in bivariate analyses and those considered clinically relevant, including: age, age >50 years, employment status, number of partners during the previous 12 months, age at first sexual relationship, use of condom, the presence of perianal or genital warts, smoking habit, history of syphilis or other sexually transmitted infection, CD4 nadir, CD4 nadir < 200 cells/\(\mu\)L, CD4 count at HIV diagnosis, CD4 count and viral load at the time of the study, receipt of ART, time with ART, and time since HIV diagnosis. A stepwise method was used, with an entry \(P\)-value of .05 and exit \(P\)-value of .10 at each step. The Hosmer–Lemeshow test was applied to analyze the goodness of fit of the model. SPSS 20.0 (IBM plc, Chicago, IL) was used for the statistical analyses. \(P < .05\) was considered significant in all tests.

3. Results

3.1. Baseline characteristics of participants

A total of 319 HIV-positive MSM were recruited between May 2010 and September 2016. The mean age was 36.7 years and the mean CD4 nadir was 361.1 cells/\(\mu\)L; CD4 nadir < 200 cells/\(\mu\)L was recorded in 24% of participants. The median time with HIV was 31 months (interquartile range [IQR]; 9–91 months); 86.2% had been on ART for a median of 19 months (IQR; 6–65.5 months), with a mean of CD4 698.5 cells/\(\mu\)L, and only 1.8% were in virological failure. Table 1 exhibits results for the remaining study variables.

3.2. Results of cytology, HPV PCR, and anal mucosa biopsy

Anal cytology results were normal in 40.3% of participants and showed LSIL in 51.1%, HSIL in 3.1%, and ASCUS in 5.3% (Fig. 1).

According to anal mucosa HPV PCR results, 311 of the 319 samples analyzed were valid. HR HPV genotypes were detected

| n, %, 95% CI | PCR HPV samples n = 311 |
|------------|-------------------------|
| HR-HPV     | 255 (81.9), (78–86)     |
| HPV-Br     | 221 (71.1), (66–76)     |
| HR-HPV and Br | 183 (59.5), (54–65)   |
| Median HR-HPV | 2 (1–3)                 |
| Median LR-HPV | 1 (0–2)                 |
| HPV 6      | 55 (17.7)               |
| HPV 11     | 56 (18)                 |
| HPV 16     | 102 (32.9)              |
| HPV 18     | 44 (14.1)               |
| HPV 31     | 45 (14.5)               |
| HPV 35     | 30 (9.6)                |
| HPV 39     | 36 (11.6)               |
| HPV 42     | 56 (18)                 |
| HPV 45     | 43 (13.9)               |
| HPV 51     | 51 (16.7)               |
| HPV 52     | 37 (11.6)               |
| HPV 53     | 54 (10.7)               |
| HPV 55     | 50 (15.7)               |
| HPV 59     | 39 (12.2)               |
| HPV 61     | 30 (9.4)                |
| HPV 62     | 40 (12.9)               |
| HPV 66     | 32 (10)                 |
| HPV 68     | 41 (13.2)               |
| HPV 81     | 36 (11.3)               |
| HR-HPV subspecies of HPV 18 (39, 45, 59, 68) | 141 (44.2) |
| HR-HPV subspecies of HPV 16 (31, 33, 35, 52, 58, 67) | 177 (55.5) |

CI = confidence interval, HPV = human papillomavirus, HR-HPV = high-risk HPV, LR-HPV = low-risk HPV, PCR = polymerase chain reaction.
in 81.9% of these (95% CI 78–86), with a median of 2 (1–3); LR-HPV genotypes were detected in 71.1% (95% CI 66–76), with a median of 1 (0–2); and simultaneous infection with low- and high-risk genotypes was detected in 59.5% (95% CI 54–65). The most frequently isolated LR-HPVs in anal mucosa were HPVs 6 (17.7%), 11 (18%), 42 (18%), 61 (9.4%), and 81 (11.3%); and the most frequently isolated HR-HPVs were HPVs 16 (32.9%), 18 (14.1%), 31 (14.5%), 45 (13.5%), 51 (16.4%), 55 (15.7%), 66 (12.9%), and 68 (13.2%) (Table 2).

Anoscopy findings were normal in 42.9% of the 319 participants and showed LSIL in 43.3%, HSIL in 13.5%, and SCCA in 0.3% (Fig. 1).

Anal mucosa biopsy findings demonstrated that 11 (25%) of the patients with normal cytology were HSIL+ (10 HSIL and 1 SCCA), whereas no HSIL+ were found in the 25 (7.8%) patients with normal cytology and negative HR-HPV PCR (Table 3). Among the 43 patients with biopsy findings of HSIL, 76.7% had evidenced abnormal cytology; among these, lesions were low-grade in 65.1%, high-grade in 11.6%, and of uncertain significance in 2.3% (Table 3). Finally, 88.8% of patients with high-grade lesions in the histologic study showed infection by high-risk virus in anal canal mucosa (Table 3).

### 3.3. HPV PCR distribution as a function of histology

The most frequently isolated HPV genotypes were HPVs 6 (16%), 16 (27%), 45 (18%), and 55 (16%) in normal biopsies; HPVs 16 (37%), 11 (20%), 42 (19%), and 55 (18%) in LSIL biopsies; and HPVs 6 (24%), 16 (38%), 18 (24%), and 68 (31%) in HSIL biopsies. Figure 2 depicts the distribution of the remaining genotypes.

Infection by genotype 16 was significantly associated with LSIL+ lesions (37.4% vs 26.7% of normal biopsies; \( P = .047 \); Kappa = 0.09; RR = 1.64; 95% CI 1.004–2.68). A significant association with HSIL+ lesions was found for genotype 68 (30.2% vs 10.3%, respectively, \( P = .0001 \); Kappa = 0.202, \( P = .0001 \); RR 3.71; 95% CI 1.7–7.9), and genotype 53 (20.9% vs 9.3%, \( P = .03 \); Kappa: 0.217, \( P = .024 \); RR = 2.37 (95% CI 1.1–5.97).

### 3.4. Predictive factors of infection by HR-HPV

In bivariate analyses, the following factors emerged as protective factors against infection by oncogenic virus: older age (36.1 vs 39.2 years, \( P = .0001 \); crude OR: 4.5), retirement (5% vs 14.3%; \( P = .017 \); crude OR: 0.32), higher CD4 cell count (675.5 vs 828.7 cells/\( \mu L \); \( P = .04 \); crude OR: 1), and viral load <50 copies/mL.
In the multiple logistic regression analysis, the only significant risk factor for infection by oncogenic HPV was CD4 nadir <200 cells/μL (OR: 3.66; 95% CI 1.03–12.75) (Table 4).

4. Discussion

A high prevalence of HPV infection in anal mucosa was observed in this cohort of MSM patients with HIV. HR-HPV genotypes were detected in 81.9% of the patients and LR-HPV genotypes in 71.1%, while both HR-HPV and LR-HPV genotypes were identified in 59.5%. The most frequently isolated genotype was HPV 16, followed by the low-risk genotypes 42, 11, and 6. An elevated prevalence of anal infection by HR- and LR-HPV was previously reported in MS patients with HIV[16] and was significantly associated with cytological abnormalities.[17] However, a lower prevalence of oncogenic viruses has been reported in Asian seropositive MSM.[18,19] This difference may be attributable to the lower age of our patients (36.7 ± 5.3 years) in comparison to the former study (46 years, range 37–56).[18,19] or to the different techniques used to detect HPV in anal mucosa.[19]

With respect to the distribution and prevalence of genotypes according to histological findings, the most frequent low-risk genotypes were: HPV 6 in patients with histologically normal mucosa, HPV 11 and 42 in LSIL, and HPV 6 in HSIL. The most frequent high-risk genotypes were HPVs 16, 45, and 55 in normal mucosa, HPVs 16 and 55 in LSIL, and HPVs 16, 18, and 68 in HSIL. The most prevalent genotype in all mucosa types was HPV 16, which was significantly associated with LSIL+ lesions. HPVs 18 and 53, less prevalent than HPV 16, were associated with the presence of HSIL+ lesions. In previous studies of seropositive and seronegative patients, the most prevalent HR-HPV in anal mucosa was genotype 16, regardless of sex or sexual orientation,[19,20] and this genotype has also been associated with high-grade lesions in seropositive MSM individuals and with other oncogenic viruses, for example, HPV 51.[21]

These results are similar to published data on the prevalence of HPV genotypes in HIV-positive MSM according to histological findings, although these showed some differences, even including the absence of LR-HPV 11 and HR-HPV 45, among others.[7] In addition, the previous study was limited by an important selection bias, given that the distribution of HPV genotypes was only analyzed in individuals with abnormal cytology and pathological HRA findings, with biopsies only being ordered for 94 (19.4%) of the 483 participants.[7]

In the present study of HIV-positive MSM with HSILs were detected in 13.5% and SCCA in 0.3%, that is, 1 out of 7 patients had these lesions, similar to a recent report on seropositive Spanish MSM in the ART era.[21,22] Around one-quarter of HSIL+ lesions were in patients whose anal mucosa cytology had been normal. Hence, if the screening for dysplastic lesions had been based on cytology alone, as recommended by the scientific societies, 10 of the patients with HSIL and the patient with SCCA could have been undiagnosed and untreated. On the other hand, we highlight that no HSIL+ lesions were detected in patients with normal cytology and negative HR-HPV PCR. Anal cytology showed only moderate sensitivity in the present series. The cytology was previously observed to be more useful in cases with high-grade lesions, a larger number of involved quadrants, HIV positivity and CD4 cell count <200 cells/μL.[23] In contrast, the majority of our patients had an excellent immune status, which

### Table 4

| Risk factors for infection by HR-HPV genotype in MSM patients with HIV bivariate and multivariate analyses. |
|--------------------------------------------------------------------------------------------------------|
| With HR-HPV N = 255 | Without HR-HPV N = 56 | Bivariate | Multivariate |
|----------------------|------------------------|-------------|-------------|
| Mean age, y, (±SD)   | 36.1 (±8.9)            | 39.4 (±11.5) | .0001; 4.5  | 0.98 (0.932–1.030) |
| Age <30 y, n, %      | 77 (30.1)              | 13 (23.2)     | .3; 1.43     | 1.001 (0.996–1.006) |
| Age 30–50 y, n, %    | 156 (61.2)             | 33 (58.9)     | .8; 1.09     | 0.73 (0.171–3.120) |
| Age >50 y, n, %      | 23 (9)                 | 10 (17.9)     | .06; 0.5     | 0.036 (0.072–1.812) |
| Retired, n, %        | 13 (5)                 | 8 (14.3)      | .017; 0.72   | 0.003 (0.001–1.059) |
| Anal partners 12 previous months (IQR)                  | 1 (1–6)                | 3 (1–11)     | .65; 0.99    | 1.004 (0.981–1.028) |
| Age at onset of sexual relationships (IQR)               | 18 (16–20)             | 18 (16–22)   | .34; 0.97    | 0.959 (0.89–1.033)  |
| Use of condom, n, % | 200 (78.4)             | 43 (76.8)     | .9; 0.98     | 0.92 (0.966–2.302)  |
| Penile/anal condyloma, n, %                            | 66 (25.9)              | 17 (30.4)     | .5; 0.8      | 0.079 (0.036–1.488)  |
| History of          |                        |              |              |              |
| Syphilis, n, %      | 57 (22.3)              | 13 (23.2)     | .9; 0.95     | 1.2 (0.49–2.89)    |
| Other ST, n, %      | 37 (14.5)              | 14 (25)       | .58; 0.8     | 1.2 (0.49–2.95)    |
| Smoking, n, %       | 131 (51.3)             | 24 (43.6)     | .25; 1.4     | 1.3 (0.75–3.07)    |
| Time since HIV diagnosis, mo (IQR)                      | 29 (9–84)              | 43.5 (9–122) | .12; 0.99    | 1.003 (0.99–1.02)   |
| CD4 at HIV diagnosis, cells/μL (±SD)                    | 459.4 (±255.61)        | 460.9 (±250.2) | .98; 1       | 1.004 (1.003) |
| CD4 nadir, cells/μL (±SD)                               | 361.1 (±209.7)         | 377.5 (±217.4) | .64; 1       | 1.007 (1.003) |
| CD4 nadir <200 cells/μL                                 | 68 (36.8)              | 9 (13.4)      | .11; 1.86    | 3.66 (1.05–12.75)   |
| At study visit                                             |                        |              |              |              |
| CD4, cells/μL (±SD)                                      | 675.4 (±203.9)         | 828.7 (±1029.4) | .04; 1       | 1.000 (0.999–1) |
| CD8, cells/μL (±SD)                                      | 1319.7 (±311.9)        | 957.1 (±327.9) | .39; 1.001  | 1.000 (1.000–1) |
| HIV VL (log) (±SD)                                       | 3.74 (±4.3)            | 2.89 (±5.12)  | .12; 1       | 1.00 (1–1)       |
| VL < 50 copies/mL                                         | 161 (70.9)             | 47 (85.4)     | .047; 0.47   | 1.125 (0.402–3.147) |
| Diagnosis of AIDS, n, %                                  | 16 (21.4)              | 72 (30.6)     | .98; 0.98    | 1.00 (1.00–1.001) |
| ART, n, %                                                 | 215 (84.3)             | 52 (92.9)     | .11; 0.41    | 1.79 (0.335–9.438) |
| Median months on ART (IQR)                               | 16.5 (6–60)            | 33.5 (6–81.5) | .09; 0.99    | 1.002 (0.989–1.016) |
| Virological failure, n, %                                | 4 (1.8)                | 1 (1.9)       | .97; 0.96    | 1.10 (0.93–1.30)   |

P-value, OR odds ratio, ART = antiretroviral therapy, CI = confidence interval, HPV = human papillomavirus, HR-HPV = high-risk HPV, IQR = interquartile range, MSM = men who have sex with men, VL = viral load.
predicts low sensitivity for cytology results. It therefore appears essential to optimize the screening of precursor and anal cancer lesions in HIV-infected MSM. We therefore propose that HPV PCR is performed in patients with normal cytology, because a negative result would rule out HSL+ lesions in all such cases. Other authors have proposed the utilization of HRA in screening for these lesions, based on the high frequency of false-negative cytology results in screening for intraepithelial lesions. Finally, the sole predictive factor for HR-HPV anal infection in the multiple logistic regression analysis was a CD4 nadir <200 cells/µL. This factor may also explain the higher rate of HPV infection reported in seropositive versus seronegative MSM patients.”

References

[1] Park BI, Introcio C, Dunne EF. Human papillomavirus and genital warts: a review of the evidence for the 2015 centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 2015;61:5849–53.

[2] Jemal A, Smard EP, Dorell C, et al. Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013;105:173–201.

[3] http://seer.cancer.gov/statfacts/html/anus.html#incidence-mortality. [Accessed April 11, 2011].

[4] Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Inf Dis 2012;54:1026–34.

[5] Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009;27:884–90.

[6] Oehler-Janne C, Huguet F, Provencher S, et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 2008;26:5550–7.

[7] Darwich L, Videla S, Cañadas MP, et al. Distribution of human papillomavirus genotypes in anal cytological and histological specimens from HIV-infected men who have sex with men and men who have sex with women. Dis Colon Rectum 2013;56:1043–52.

[8] Hidalgo-Tenorio C, Rivera-Rodriguez M, Gil-Anguita C, et al. The role of polymerase chain reaction of high-risk human papilloma virus in the screening of high-grade squamous intraepithelial lesions in the anal mucosa of human immunodeficiency virus-positive males having sex with males. PLoS One 2015;10:e0123590.

[9] Salit IE, Lytwyn A, Raboud J, et al. The role of cytology (Pap test) and human papillomavirus testing in anal cancer screening. AIDS 2011;24: 1307–15.

[10] Padilla-España L, Repiso-Jiménez B, Fernández-Sánchez F, et al. Usefulness of human papillomavirus testing in anal intraepithelial neoplasia screening in a risk behaviour population. Enferm Microbiol Clin 2014;32:560–4.

[11] Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–27.

[12] Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002;287: 2114–9.

[13] Darragh TM, Colgan TJ, Cox JT, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012;16:205–42.

[14] Andrés AM, Marzo PF. Chance-corrected measures of reliability and validity in K x k tables. Stat Methods Med Res 2005;14:473–92.

[15] Freeman DH. Applied Categorical Data Analysis. Marcel Dekker, New York, USA:1987.

[16] Nowak RG, Gravitt PE, He X, et al. Prevalence of anal high-risk human papillomavirus infections among HIV-positive and HIV-negative men who have sex with men in Nigeria. Sex Transm Dis 2016;43:243–8.

[17] Latini A, Dona MC, Roncetti L, et al. Prevalence of anal human papillomavirus infection and cytologic abnormalities among HIV-infected and HIV-uninfected men who have sex with men. J Int AIDS Soc 2014;17(Suppl 3):19662.

[18] Lee CH, Lee SH, Lee S, et al. Anal human papillomavirus infection among HIV-infected men in Korea. PLoS One 2016;11:e0161460.

[19] Hu Y, Qian HZ, Sun J, et al. Anal human papillomavirus infection among HIV-infected and uninfected men who have sex with men in Beijing, China. J Acquir Immune Defic Syndr 2013;64:103–14.

[20] Schim van der Loef MF, Mooij SH, Richel O, et al. HPV and anal cancer in HIV-infected individuals: a review. Curr HIV/AIDS Rep 2014;11: 250–62.

[21] Sendagorta E, Herranz P, Guadalajara H, et al. Prevalence of abnormal anal cytology and high-grade squamous intraepithelial lesions among a cohort of HIV-infected men who have sex with men. Dis Colon Rectum 2015;57:475–81.

[22] Iribarren Díaz M, Ocampo Hermida A, González-Carreró Fojón J, et al. Preliminary results of a screening program for anal cancer and its precursors for HIV-infected men who have sex with men in Vigo-Spain. Rev Esp Enferm Dig 2017;109:242–9.

[23] Nathan M, Singh N. Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings. AIDS 2010;24:373–9.

[24] Schofeld AM1, Sadler L, Nelson L, et al. A prospective study of anal cancer screening in HIV-positive and negative MSM. AIDS 2016;30: 1375–83.

[25] Mooij SH1, van Santen DK, Geskus RB, et al. The effect of HIV infection on anal and penile human papillomavirus incidence and clearance: a cohort study among MSM. AIDS 2016;30:121–32.

[26] Videla SI, Darwich L, Cañadas MP, et al. Natural history of human papillomavirus infections involving anal, penile, and oral sites among HIV-positive men. Sex Transm Dis 2013;40:3–10.

[27] Chaturvedi AK, Madeleine MM, Biggar RJ, et al. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009;101:1120–30.